Equities

Proteome Sciences PLC

PRM:LSE

Proteome Sciences PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1.77
  • Today's Change0.015 / 0.85%
  • Shares traded504.75k
  • 1 Year change-58.25%
  • Beta0.7833
Data delayed at least 20 minutes, as of Feb 06 2026 16:29 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Proteome Sciences plc is a specialist provider of contract proteomics services. The Company’s services enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. Its principal activities involve protein biomarker research and development. It uses high-sensitivity techniques to detect and characterize differentially expressed proteins in biological samples for diagnostic, prognostic and therapeutic applications. SysQuant and TMT MS2 are unbiased methods for identifying and contextualizing new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. In addition, it has invented and developed the technology for TMT and TMTpro, and manufactures these small, protein-reactive chemical reagents for multiplex quantitative proteomics.

  • Revenue in GBP (TTM)4.53m
  • Net income in GBP-3.33m
  • Incorporated1993
  • Employees36.00
  • Location
    Proteome Sciences PLCCoveham House, Downside Bridge RoadADDLESTONE KT11 3EPUnited KingdomGBR
  • Phone+44 20 7043 2116Fax+44 20 3637 7516
  • Websitehttps://www.proteomics.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Image Scan Holdings Plc1.62m-288.02k1.98m13.001.98m13.00
Genincode PLC2.91m-4.97m3.30m36.003.30m36.00
Surgical Innovations Group Plc11.92m-1.44m4.20m88.004.20m88.00
Cambridge Nutritional Sciences PLC8.06m1.37m4.76m84.004.76m84.00
Feedback plc885.62k-7.32m4.89m28.004.89m28.00
Proteome Sciences plc4.53m-3.33m6.21m36.006.21m36.00
Rua Life Sciences PLC5.17m-850.00k9.00m33.009.00m33.00
Verici DX PLC1.41m-5.60m10.90m15.0010.90m15.00
Genedrive PLC954.00k-5.23m11.84m43.0011.84m43.00
Cellbxhealth PLC2.62m-15.78m11.96m119.0011.96m119.00
Abingdon Health PLC8.43m-3.42m15.06m121.0015.06m121.00
Inspiration Healthcare Group PLC45.20m-11.44m15.24m214.0015.24m214.00
Data as of Feb 06 2026. Currency figures normalised to Proteome Sciences PLC's reporting currency: UK Pound GBX

Institutional shareholders

39.25%Per cent of shares held by top holders
HolderShares% Held
Vulpes Investment Management Pte Ltd.as of 29 Jan 202684.93m28.77%
Hargreaves Lansdown Fund Managers Ltd.as of 01 Dec 202519.06m6.46%
Rathbones Investment Management Ltd.as of 01 Dec 20252.90m0.98%
IG Markets Ltd.as of 01 Dec 20252.62m0.89%
Rowan Dartington & Co. Ltd. (Broker)as of 01 Dec 20252.36m0.80%
James Brearley & Sons Ltd.as of 01 Dec 20252.31m0.78%
J. M. Finn & Co. Ltd.as of 01 Dec 2025638.00k0.22%
iDealing.com Ltd.as of 01 Dec 2025444.00k0.15%
Charles Schwab Investment Management, Inc.as of 01 Dec 2025295.00k0.10%
HSBC Global Asset Management (UK) Ltd.as of 01 Dec 2025294.00k0.10%
More ▼
Data from 31 Jan 2025 - 29 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.